/Investor DB

Richard King Mellon Foundation — 2020 Investments

1 investments dated 2020 · listed companies and verified rows first · show all

Cytoagents Inc.cytoagents.cominJul 2020

CytoAgents is a clinical-stage biopharmaceutical company developing therapies for the life-threatening symptoms of Cytokine Release Syndrome (CRS), an immune overreaction causing systemic inflammation.

BiotechHealthtechPittsburgh, US

Teresa Whalen, RPh(Chief Executive Officer)inCatherine Mott(Director)Teresa Whalen(Chief Executive Officer)Anthony McCarley(Director)John Friedman(Director)Stanley Marks(Director)

Co-investorsBoston Harbor AngelsDelaware Crossing Investor GroupEQx FundMountain State Capital

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.